全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Your location:Home > Faculty > Principal Investigator
Yushe Yang 杨玉社

Name:Yushe Yang 杨玉社 Title:Principal Investigator Education:Ph.D Contact Number:0760-85286866 E-mail:ysyang@simm.ac.cn Address:SSIP Healthcare and Medicine Demonstration Zone, Zhongshan Tsuihang New District, Guangdong 528400

  • Biography

    Prof. Yang received his B.S. in chemistry (1987) and M.S. in organic chemistry (1990) from Sichuan University, and Ph.D. (1996) from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, under the supervision of Prof. Ruyun Ji. Upon completion of his postdoctoral research in the same group, he joined the SIMM as faculty in 1998. He is now a professor of medicinal chemistry and Principal Investigator at SIMM and Zhongshan Institute for Drug Discovery (ZIDD).

  • Research Directions

    Prof. Yang's research interests focus on new drug discovery and development, spanning anti-infectives, anticoagulants, anticancer drugs and central nervous system drugs.

  • Achievements

    Prof. Yang has been dedicated to new drug discovery and development for over twenty years and has accumulated a wealth of knowledge and experience in the field antibiotics, anticancer drugs and anticoagulants. His endeavors in the field have brought many accomplishments, including two “class 1.1 new drug” certificates. A representative achievement in Yang’s Lab is the successful development of Antofloxacin Hydrochloride, an innovative fluoroquinolone antibiotic. With superior safety, efficacy and pharmacokinetic (PK) profiles over other antibiotics, Antofloxacin was approved by the China Food and Drug Administration (CFDA) (now NMPA) in 2009. It is the first class 1.1 new drug in the family of fluoroquinolone with independent intellectual property in China, and the first-ever new chemical entity (NCE) developed by Chinese scientists in China since 1993, filling the gap of this field in China. He also led and significantly contributed to the development of other candidates, including YG-001, an FXa inhibitor as anticoagulant, approved for IND by China NMPA, YG-056SP, an oxazolidinone antibiotic, and YZS-103, a spiropyrimidinetrione antibiotic, which are being submitted to NMPA for IND application. These candidates have been transferred to pharmaceutical enterprises for joint development.

    Prof. Yang has published over 70 research papers (12 published in J. Med. Chem) and holds more than 30 issued patents.

    Prof. Yang has won a number of awards and honors for his research accomplishments, including the Second Prize of National Technology Invention Award (the first contributor) in 2017, the First Prize of Shanghai Science and Technology Award for Technical Invention (ranking first) in 2015, the China Pharmaceutical Development Award (Innovative Drug Award), and Shanghai Advanced Worker (Model Worker).

  • Publications

    1. Zhengyu Lu, Yangzhi Cao, Dan Zhang, Xin Meng, Bin Guo*, Deyu Kong*, Yushe Yang*. Discovery of Thieno[2,3-e]indazole Derivatives as Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability. J. Med. Chem. 2022, 65(7), 5724?5750.

    2. Huijun Ma#, Anran Qian#, Yazhou Zheng, Xin Meng, Ting Wang, Yinyong Zhang, Lulu Sun, Feng Zou, Bomei Zhao, Shuhua Zhang, Dan Zhang*, and Yushe Yang*. Design, Synthesis, and Structure–Activity Relationship Studies of Bisamide Derivatives of Amphotericin B with Potent Efficacy and Low Toxicity. J. Med. Chem. 2022, 65(13), 8897?8913.

    3. Ao Wang, Xianggang Luo, Yawan Wang, Xin Meng, Zhengyu Lu, and Yushe Yang*. Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer. J. Med. Chem. 2022, 65(18), 12460?12481.

    4. Qidi Kong, Wei Pan, Heng Xu, Yaru Xue, Bin Guo, Xin Meng, Cheng Luo, Ting Wang, Shuhua Zhang, and Yushe Yang*. Design, Synthesis, and Biological Evaluation of Novel Pyrimido[4,5-b]indole Derivatives Against Gram-Negative Multidrug-Resistant Pathogens. J. Med. Chem. 2021, 64(12), 8644?8665.

    5. Chenghui Shi#, Yinyong Zhang#, Ting Wang, Wenchao Lu, Shuhua Zhang, Bin Guo, Qian Chen, Cheng Luo, Xianli Zhou*, and Yushe Yang*, Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria. J. Med. Chem. 2019, 62(6), 2950?2973.

    6. Deyu Kong, Tao Xue, Bin Guo, Jianjun Cheng, Shunyin Liu, Jianhai Wei, Zhengyu Lu, Haoran Liu, Guoqing Gong, Tian Lan, Wenhao Hu*, and Yushe Yang*,Optimization of P2Y12 Antagonist Ethyl 6?(4-((Benzylsulfonyl) carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties. J. Med. Chem. 2019, 62(6), 3088?3106.

    7. Liang Tan, Yunliang Tao, Ting Wang, Feng Zou, Shuhua Zhang, Qun huan Kou, Ao Niu, Qian Chen, Wenjing Chu,Xiaoyan Chen, Haidong Wang*, and Yushe Yang*. Discovery of Novel Pyridone-Conjugated Monosulfactams as Potent and Broad-Spectrum Antibiotics for Multidrug-Resistant Gram-Negative Infections. J. Med. Chem. 2017, 60(7), 2669–2684.

    8. Tao Xue, Shi Ding, Bin Guo*, Yuren Zhou, Peng Sun, Heyao Wang, Wenjing Chu, Guoqing Gong, Yinye Wang, Xiaoyan Chen, and Yushe Yang*. Design, Synthesis, and Structure-Activity and Structure-Pharmacokinetic Relationship Studies of Novel [6,6,5] Tricyclic Fused Oxazolidinones Leading to the Discovery of a Potent, Selective, and Orally Bioavailable FXa Inhibitor. J. Med. Chem. 2014, 57(18), 7770?7791.

    9. Chenyu Ling, Liqiang Fu, Suo Gao, Wenjing Chu, Hui Wang, Yanqin Huang, Xiaoyan Chen, and Yushe Yang*. Design, Synthesis, and Structure-Activity Relationship Studies of Novel Thioether Pleuromutilin Derivatives as Potent Antibacterial Agents. J. Med. Chem. 2014, 57(11), 4772?4795.

    10. Xufeng Cao#, Zhaoshuan Sun#, Yongbing Cao, Ruilian Wang, Wenjing Chu, Wenhao Hu*, Yushe Yang,* Design, Synthesis, and Structure–Activity Relationship Studies of Novel Fused-Heterocycle- Linked Triazoles with High Activity and Water Solubility. J. Med. Chem. 2014, 57(9), 3687?3760.

    11. Bin Guo, Houxing Fan, Qisheng Xin, Wenjing Chu, Hui Wang, Yanqin Huang, Xiaoyan Chen, and Yushe Yang*. Solubility-Driven Optimization of (Pyridin-3-yl) Benzoxazinyl-oxazolidinones Leading to a Promising Antibacterial Agent. J. Med. Chem. 2013, 56(6), 2642?2650.

    12. Qisheng Xin#, Houxing Fan#, Bin Guo, Huili He, Suo Gao, Hui Wang, Yanqin Huang, Weiliang Zhu, Yushe Yang*. Design, Synthesis, and Structure–Activity Relationship Studies of Highly Potent Novel Benzoxazinyl-Oxazolidinone Antibacterial Agents. J. Med. Chem. 2011, 54(21), 7493?7502.

    点击展开 ?

Tel:86-760-85286866 Fax:0086-760-85283266 Address:SSIP Healthcare and Medicine Demonstration Zone, Zhongshan Tsuihang New District, Guangdong 528400

Wechat
Zhongshan Institute for Drug Discovery 粤ICP备20032354号 By Wanhu